News on trends and issues in the biopharm and pharmaceutical industry. Commentary on current events,clinical pipelines, facility expansions, competition, technology, legal and economic matters. M&A and licensing activity across the globe.
I am a Director of Research and Devopment for a leading supplier to biopharmaceutical producers. The views expressed are mine. I do not speak for any company or corporation.
In an effort to be more visible to the public, the FDA now publishes its own 'transparency blog". This post deals with their role in regulating orphan drugs in service of the 7000+ rare diseases.